EW240920C70000
- 0.27
- -0.13-32.50%
Edwards Lifesciences Newsroom
Edwards Lifesciences Downgraded at Jefferies on Lower TAVR Growth
Jefferies Maintains Edwards Lifesciences(EW.US) With Hold Rating, Maintains Target Price $70
Edwards Lifesciences Analyst Ratings
Wells Fargo Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $80
Jefferies Downgrades Edwards Lifesciences(EW.US) to Hold Rating, Cuts Target Price to $70
Jefferies Downgrades Edwards Lifesciences to Hold From Buy, Adjusts Price Target to $70 From $85
Edwards Lifesciences: Hold Rating Amid TAVR Sector Challenges and Growth Constraints
BofA Securities Downgrades Edwards Lifesciences(EW.US) to Hold Rating, Cuts Target Price to $75
Truist Financial Downgrades Edwards Lifesciences(EW.US) to Hold Rating
Edwards Lifesciences Price Target Maintained With a $90.00/Share by Oppenheimer
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), MoonLake Immunotherapeutics (MLTX) and Protara Therapeutics (TARA)
Oppenheimer Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $90
UBS Maintains Neutral on Edwards Lifesciences, Lowers Price Target to $75
UBS Maintains Edwards Lifesciences(EW.US) With Hold Rating, Cuts Target Price to $75
Barclays Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $80
Edwards Lifesciences Is Maintained at Overweight by Wells Fargo
Edwards Lifesciences Analyst Ratings
Wells Fargo Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $80
Barclays Maintains Edwards Lifesciences(EW.US) With Buy Rating, Cuts Target Price to $80
Wells Fargo Maintains Edwards Lifesciences(EW.US) With Buy Rating, Cuts Target Price to $80